Kodiak Sciences Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Kodiak announced positive Phase 3 DAYBREAK results (September 2026): Zenkuda (tarcocimab tedromer) achieved non-inferiority to aflibercept (p=0.0007) with 54% of patients on 6-month dosing intervals using treat-to-dryness criteria; tabirafusp-ted met vision primary endpoint (p=0.0036) and anatomical secondary endpoint (p=0.0001). The company plans a multi-indication BLA submission for Zenkuda in Q4 2026 covering wet AMD, diabetic retinopathy, and retinal vein occlusion based on five completed Phase 3 studies, with KSI-101 Phase 3 data expected December 2026 and potential two drug approvals by end of 2027/early 2028.
Why this rating
Pivotal clinical success de-risks a pre-commercial company's lead asset (Zenkuda) and validates multi-indication strategy. Three late-stage programs approaching regulatory decision represent material fraction of $121.6M market cap; approval path now clear. Significant but not certainty until FDA decision.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $61.00 ▼ 2.44% | at our read · unknown $62.52 | +10 min · unknown $70.50 ▲ 12.75% | +30 min · unknown $76.52 ▲ 22.39% | +1 hr pending | +4 hrs pending |
The stock had already moved +2.50% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.